Navigation Links
FDA Approves Label Update for PREZISTA® to Include 192-Week Data in HIV-1-Infected Adult Patients Starting Treatment
Date:10/21/2011

ResultsThe ARTEMIS study compared the efficacy and safety of PREZISTA/r 800/100 mg once daily (n=343) versus lopinavir/r 800/200 mg total daily dose (n=346) in treatment-naive adults with HIV-1. All patients received a fixed-dose combination of tenofovir and emtricitabine once daily. At 192 weeks, PREZISTA/r was shown to be non-inferior to lopinavir/r. This 192 week analysis showed that:

-- 70% of patients in the PREZISTA/r arm reached an undetectable viral load (less than 50 copies/m.) vs. 61% of patients in the lopinavir/r arm.  Virologic failure was 12% in the PREZISTA/r arm and 15% in the lopinavir/r arm. Statistical superiority of PREZISTA/r over the lopinavir/r regimen was demonstrated in both the intent-to-treat (ITT) and on-protocol (OP) analysis.

-- The most common treatment-related adverse reactions (greater or equal to 5 percent) of moderate intensity (greater or equal to grade 2) among patients in the PREZISTA/r arm vs. lopinavir/r arm were: diarrhea (9 percent vs. 16 percent); headache (7 percent vs. 6 percent); abdominal pain (6 percent vs. 6 percent); and rash (6 percent vs. 7 percent).

About the ARTEMIS StudyARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naive Subjects) is an international, randomized, controlled, open-label, non-inferiority, Phase 3 trial that compared the efficacy and safety of PREZISTA/r versus lopinavir/r in treatment-naive HIV-1-infected adult patients with viral load greater than 5,000 copies/mL.

The main objective of the study was to demonstrate non-inferiority of PREZISTA/r versus lopinavir/r in the proportion of patients achieving virologic response, defined as confirmed HIV RNA less than 50 copies/mL. Non-inferiority of PREZISTA/r vs. lopinavir/r was defined as a maximum allowable difference of 12 percent for virologic response, with a one-sided significance level of alpha equal to 0.025.

Important Safety Information PREZISTA does not cure HIV-1 infection or AIDS, and
'/>"/>

SOURCE Janssen Therapeutics, Division of Janssen Products, LP
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
2. FDA Approves Combination Therapy Juvisync
3. FDA Approves Cialis to Treat Benign Prostatic Hyperplasia
4. FDA Approves Remicade to Treat Ulcerative Colitis in Children Older Than 6 Years
5. FDA Approves Soliris for Rare Pediatric Blood Disorder
6. FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
7. FDA Approves Xalkori with Companion Diagnostic for a Type of Late-stage Lung Cancer
8. FDA Approves Firazyr To Treat Acute Attacks of Hereditary Angioedema
9. FDA Approves Adcetris to Treat Two Types of Lymphoma
10. FDA Approves the First Specific Treatment for Scorpion Stings
11. Cardinal Health Board of Directors Approves Cash Dividend, Elects David P. King as Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Virginia , 11. Juli 2014 ... von Kameras für die molekulare Bildgebung, ... hat heute die CE-Zulassung für sein ... CE-Zeichen kann Dilon das Produkt jetzt ... auf den Großteil der europäischen Länder ...
(Date:7/10/2014)... -- RESMED INC. (NYSE: RMD ) today announced that ... June 30, 2014 results on Thursday, July 31, 2014, after ... with ResMed,s results will be issued after 1:00 p.m. US ... discuss operating results and future outlook. The earnings ... Time and the live webcast of the call can be ...
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... MESA, Ariz., Dec. 6, 2011   Ulthera ... device company pioneering aesthetic and medical applications ... today announced that it has named Greg ... newly created position at Ulthera. ...
... Industries, Inc. (OTC.PK:PDMI) announced that it is continuing to move ... the limited working capital and market concerns it has had ... the mettle of Paradigm, its shareholders and remaining loyal employees. ... close, Paradigm remains hopeful it will see the DTC "chill" ...
Cached Medicine Technology:Ulthera Appoints Greg Waller as Chief Financial Officer 2Paradigm Business Update as of November 30, 2011 2
(Date:7/13/2014)... decreased ability to identify odors might indicate the ... examinations of the eye could indicate the build-up ... the brain, according to the results of four ... International Conference 2014 (AAIC 2014) in Copenhagen. , ... to identify odors was significantly associated with loss ...
(Date:7/13/2014)... 2014 Wright & Schulte LLC has ... scheduled in July of 2015, in U.S. District Court, ... in the discovery process in the South Carolina ... presiding over the multidistrict litigation (MDL). The complaints pending ... individuals who allege that they took the statin medication ...
(Date:7/13/2014)... 2014 Celebrity fitness trainer and former ... promotional partnership with Aqua Health Labs for their flagship ... supplement . The collaboration was recently announced live on ... trainer , actor, model, and a two time World ... celebrities, he has prepared stars including Demi Moore, Hilary ...
(Date:7/13/2014)... Illinois (PRWEB) July 13, 2014 Hope Palliative ... a monthly grief support group at the Tamarack Senior Living ... be held at 10:30 A.M. on the 3rd Wednesdays of ... 16th, 2014 at the Tamarack Community located at 55 S. ... all bereaved individuals and there is no cost for the ...
(Date:7/13/2014)... 2014 According to The Peripheral Neuropathy ... comprehensive program that teaches people how to deal with ... without medications. This program also provides people with safe ... neuropathy , including numbness, prickling, burning, and intense stabbing ... this home treatment program can help people eliminate some ...
Breaking Medicine News(10 mins):Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3
... Brody, Ph.D., assistant professor, Department of Surgery at Jefferson ... a 2010 Pancreatic Cancer Action Network American Association ... of Skip Viragh. This two-year grant awards $200,000 ... in pancreatic cancer. He will receive recognition for ...
... ... Action For Healthy Kids , was honored to be one of only 10 ... "Let,s Move" initiative to end childhood obesity in a generation. Flis was ... from D.C. and taking this opportunity to launch a Call to Action ...
... Douglas Smith, ... Officer; calls Consult A Doctor “the next evolution in medical care delivery, increasing access and ... Miami, FL ... Smith, board-certified family practice physician and pioneer of retail medical clinics, has joined as its ...
... ... Otology and Neurotology a “Letter to the Editor” documenting the improvement for memory loss ... focuses on two recent cases that were referred to Dr. Lippy, following stapedectomy surgery ... ...
... ... Music Announce April 13 Release , ... Los Angeles (PRWEB) April 14, 2010 -- LML Music announces the April ... the National Multiple Sclerosis Society. ,in my room, was conceived and produced by LML recording ...
... ... mobile networks will rise to almost $1.9 billion globally by 2014, with heart based monitoring ... ... According to Juniper Research, revenues from remote patient monitoring using mobile networks will rise to ...
Cached Medicine News:Health News:Jefferson researcher receives 2010 Pancreatic Cancer Action Network-AACR Career Development Award 2Health News:Mom Returns From D.C. Determined To Take On Childhood Obesity With A Call To Action For Parents 2Health News:Mom Returns From D.C. Determined To Take On Childhood Obesity With A Call To Action For Parents 3Health News:Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer 2Health News:Consult A Doctor, Inc. Names Retail Clinic Pioneer, Douglas Smith, M.D. as Chief Medical Officer 3Health News:New Study Identifies Cause of Severe Disequilibrium and Significant Memory Loss Following Stapedectomy Surgery 2Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 2Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 3Health News:Peter Bradley Adams, Victoria Shaw, Many Distinguished Colleagues Ally To Benefit National MS Society With CD Release: In My Room 4Health News:Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research 2Health News:Revenues from Mobile Health Monitoring to Reach $1.9 Billion Globally by 2014 Says Juniper Research 3
... 220XiIII quickly prints labels up ... 10 ips. It is ideal ... as printing chemical drum labels, ... industry labels, banner-sized labels and ...
... bedside Transfusion Verification System, is used ... patient receives the specific unit(s) of ... for them. It has the additional ... through their institution's policy and procedure ...
... helps ensure a safe care environment by automatically ... the unit dose level. The automated process and ... location and handling of all items, including vials, ... and more. This saves valuable time for pharmacy ...
... The Transfusion Safety Management system ensures ... products and care. , BloodTrack SafeTx uses ... the patient from sample collection to transfusion. ... transfused and reduces the need for bedside ...
Medicine Products: